{"nctId":"NCT00383019","briefTitle":"A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH).","startDateStruct":{"date":"2006-11-14","type":"ACTUAL"},"conditions":["Glaucoma","Ocular Hypertension"],"count":300,"armGroups":[{"label":"Xalatan","type":"EXPERIMENTAL","interventionNames":["Drug: Xalatan"]},{"label":"Xalacom","type":"EXPERIMENTAL","interventionNames":["Drug: Xalacom"]}],"interventions":[{"name":"Xalatan","otherNames":[]},{"name":"Xalacom","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Intraocular pressure is 18 mmHg or more at baseline after treatment with Xalatan for 4 weeks or more.\n\nExclusion Criteria:\n\n* History of no-response to timolol\n* History of trabeculectomy\n* History of other ocular surgery including ALT, SLT,and trabeculotomy within 6 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change of Intraocular Pressure (IOP) From Baseline to Week 8","description":"Value at Week 8 minus value at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.59","spread":null},{"groupId":"OG001","value":"-1.62","spread":null}]}]}]},{"type":"SECONDARY","title":"Change of IOP From Baseline to Week 4","description":"Value at Week 4 minus value at baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.50","spread":null},{"groupId":"OG001","value":"-1.17","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With an IOP of <=15 mmHg at Week 8","description":"Number of subjects who achieved IOP reduction to 15 mmHg or below at Week 8","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With an IOP of <=16 mmHg at Week 8","description":"Number of subjects who achieved IOP reduction to 16 mmHg or below at Week 8","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change of IOP From Baseline to Week 8","description":"Value at Week 8 minus value at baseline was divided by baseline value, then multiplied by 100","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.67","spread":null},{"groupId":"OG001","value":"-7.69","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With an IOP of <=18 mmHg at Week 8","description":"Number of subjects who achieved IOP reduction to 18 mmHg or below at Week 8","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With an IOP Reduction of >=2 mmHg From Baseline to Week 8","description":"Number of subjects whose IOP were reduced by 2 mmHg or more at Week 8 from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95","spread":null},{"groupId":"OG001","value":"65","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With an IOP Reduction of >=3 mmHg From Baseline to Week 8","description":"Number of subjects whose IOP were reduced by 3 mmHg or more at Week 8 from baseline","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With an IOP of <=17 mmHg at Week 8","description":"Number of subjects who achieved IOP reduction to 17 mmHg or below at Week 8","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83","spread":null},{"groupId":"OG001","value":"60","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":144},"commonTop":["Eye irritation","Nasopharyngitis","Punctate keratitis","Conjunctival hyperaemia","Eczema"]}}}